StreetInsider.com News Articles

Invivyd to Participate in Upcoming September Investor Conferences

Tue, 08 Sep 2026 07:01:00 -0400

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Fireside Chat: Monday,

Invivyd to Participate in Upcoming September Investor Conferences

Tue, 08 Sep 2026 07:01:00 -0400

Citi’s 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Fireside Chat: Monday,

Invivyd names chairman Marc Elia as CEO ahead of VYD2311 data

Tue, 01 Sep 2026 07:02:47 -0400

Invivyd, Inc. (Nasdaq: IVVD) has appointed Marc W. Elia, its current Chairman of the Board of Directors, as Chief Executive Officer, according to a press release issued by the company. Elia will hold both the Chairman and CEO roles going forward.

Elia has served as Chairman of Invivyd's board since June 2022. Ajay Royan, founder of Mithril Capital and a long-term investor in Invivyd, has been appointed Lead Independent Director. Ian Sheffield, founder and Managing Partner of North Country Holdings, a private investment firm, has joined the board as an independent director. Sheffield has more than 20 years of experience as

Invivyd names chairman Marc Elia as CEO ahead of VYD2311 data

Tue, 01 Sep 2026 07:02:47 -0400

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Tue, 01 Sep 2026 07:01:00 -0400

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy
Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director
Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director
DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Tue, 01 Sep 2026 07:01:00 -0400

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy
Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director
Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director
DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as

Invivyd Inc. (IVVD) Reiterated at Overweight by Cantor Fitzgerald

Thu, 27 Aug 2026 07:27:23 -0400

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $10.00 price target on Invivyd Inc. (NASDAQ: IVVD).

The analyst commented, "Last week marked the launch of our weekly COVID tracker series. We're keeping a close eye on COVID trends, particularly given their relevance to IVVD's DECLARATION study, which is evaluating the monoclonal antibody VYD2311 for COVID prevention. The DECLARATION study is likely in its final weeks of patient data collection. We're seeing more hotspots emerge nationally, including in regions where IVVD has active clinical sites — a dynamic we view as a positive signal ahead of the upcoming data readout."

For

Form 4 Invivyd, Inc. For: Aug 15 Filed by: Andersen Jill